Featured Research

from universities, journals, and other organizations

Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells

Date:
November 7, 2011
Source:
University of Colorado Denver
Summary:
Within many hormone-receptor positive breast cancers lives a subpopulation of receptor-negative cells – knock down the hormone-receptor positive cells with anti-estrogen drugs and you may inadvertently promote tumor takeover by more dangerous, receptor-negative cells. A new study describes how to switch these receptor-negative cells back to a state that can be targeted by existing hormone therapies.

Estrogen-receptor positive cells live alongside a subpopulation of "triple-negative" cells in a single breast cancer. Inhibiting "Notch signalling" converts these triple-negative cells into more treatable, estrogen-receptor positive cells.
Credit: Image courtesy of University of Colorado Denver

Within many hormone-receptor positive breast cancers lives a subpopulation of receptor-negative cells -- knock down the hormone-receptor positive cells with anti-estrogen drugs and you may inadvertently promote tumor takeover by more dangerous, receptor-negative cells. A study recently published in the Proceedings of the National Academy of Sciences describes how to switch these receptor-negative cells back to a state that can be targeted by existing hormone therapies.

Related Articles


"We found that these estrogen-receptor negative cells express high levels of a Notch receptor protein," says James Haughian, PhD, investigator at the University of Colorado Cancer Center and instructor at the University of Colorado School of Medicine. "And when you blockade this Notch activity, you end up with a pure population of hormone-receptor positive cells."

Very basically, within a breast cancer, you frequently have different kinds of cells living together -- some that have estrogen receptors and thus need to "grab" estrogen in order to survive, grow and replicate. And, Haughian finds, some with similar Notch receptors that need to "grab" Notch proteins in order to survive, grow and replicate. On cells without estrogen receptors but with Notch receptors, they blockade this Notch pathway and the cell again becomes dependent on estrogen -- and thus likely treatable with anti-estrogen therapies.

"It's rare to get something that works so fantastically well as this," Haughian says.

Whether this switch from hormone-insensitive to hormone-sensitive is due to basic evolution -- killing the triple-negative cells leaves more resources for the growth of hormone-receptor positive cells -- or whether inhibiting Notch signaling, in fact, causes triple-negative cells to grow hormone receptors is still under investigation.

Whatever the precise mechanism, drugs that inhibit this Notch activity are already in clinical trials for breast cancer. However, Kathryn Horwitz, PhD, investigator at the CU Cancer Center and Distinguished Professor of Endocrinology at the CU School of Medicine theorizes that, "Monotherapy with a Notch inhibitor might not be enough on its own, but may convert the cancer into a hormone-therapy treatable state."

This finding that Notch inhibition converts a triple-negative cancer subpopulation to a hormone-receptor positive population implies the potential usefulness of combination therapy -- perhaps a Notch inhibitor to make all the cancer's cells hormone-sensitive, followed by an anti-estrogen to treat them.

"Theorizing that and proving it is another matter," Horwitz says. "But if a clinician came knocking on our door, we'd say hey, let's try it."


Story Source:

The above story is based on materials provided by University of Colorado Denver. The original article was written by Garth Sundem. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. M. Haughian, M. P. Pinto, J. C. Harrell, B. S. Bliesner, K. M. Joensuu, W. W. Dye, C. A. Sartorius, A. C. Tan, P. Heikkila, C. M. Perou, K. B. Horwitz. Breast Cancer Special Feature: Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proceedings of the National Academy of Sciences, 2011; DOI: 10.1073/pnas.1106509108

Cite This Page:

University of Colorado Denver. "Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells." ScienceDaily. ScienceDaily, 7 November 2011. <www.sciencedaily.com/releases/2011/11/111101141347.htm>.
University of Colorado Denver. (2011, November 7). Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2011/11/111101141347.htm
University of Colorado Denver. "Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells." ScienceDaily. www.sciencedaily.com/releases/2011/11/111101141347.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins